Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length
1 other identifier
interventional
42
1 country
1
Brief Summary
To determine if uterine cavity length on transabdominal pelvic ultrasound corresponds to uterine cavity length at time of IUD insertion. If transabdominal pelvic ultrasound is validated as a tool for measuring uterine cavity length, it can be used to guide physicians and subsequently patients in IUD insertion planning.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2020
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 6, 2020
CompletedFirst Submitted
Initial submission to the registry
June 8, 2020
CompletedFirst Posted
Study publicly available on registry
June 11, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2023
CompletedFebruary 28, 2023
February 1, 2023
3 years
June 8, 2020
February 24, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Quantify Temporal Relationship between Transabdominal Ultrasound and Uterine Sound
To determine if uterine cavity length on ultrasound corresponds to uterine cavity length at time of IUD insertion
Within 60 days of enrollment
Study Arms (1)
Transabdominal Ultrasound
OTHERAll patients enrolled will undergo a transabdominal ultrasound at a specified time point as outlined in the protocol.
Interventions
Eligibility Criteria
You may qualify if:
- IUD inserted between 12/1/19 and 12/1/20
- Received a transabdominal US of the uterus
You may not qualify if:
- US never performed
- Mullerian anomaly
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's Mercy Hospital
Kansas City, Missouri, 64108, United States
Related Publications (4)
Usinger KM, Gola SB, Weis M, Smaldone A. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review. J Pediatr Adolesc Gynecol. 2016 Dec;29(6):659-667. doi: 10.1016/j.jpag.2016.06.007. Epub 2016 Jul 4.
PMID: 27386754BACKGROUNDSavasi I, Jayasinghe K, Moore P, Jayasinghe Y, Grover SR. Complication rates associated with levonorgestrel intrauterine system use in adolescents with developmental disabilities. J Pediatr Adolesc Gynecol. 2014 Feb;27(1):25-8. doi: 10.1016/j.jpag.2013.08.010. Epub 2013 Dec 4.
PMID: 24315712BACKGROUNDDizon CD, Allen LM, Ornstein MP. Menstrual and contraceptive issues among young women with developmental delay: a retrospective review of cases at the Hospital for Sick Children, Toronto. J Pediatr Adolesc Gynecol. 2005 Jun;18(3):157-62. doi: 10.1016/j.jpag.2005.03.002.
PMID: 15970247BACKGROUNDLacy J. Clinic opinions regarding IUCD use in adolescents. J Pediatr Adolesc Gynecol. 2006 Aug;19(4):301-3. doi: 10.1016/j.jpag.2006.05.013. No abstract available.
PMID: 16873036BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ashli Lawson, MD
Children's Mercy Hospital Kansas City
- PRINCIPAL INVESTIGATOR
Julie Strickland, MD
Children's Mercy Hospital Kansas City
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Physician
Study Record Dates
First Submitted
June 8, 2020
First Posted
June 11, 2020
Study Start
January 6, 2020
Primary Completion
December 31, 2022
Study Completion
February 1, 2023
Last Updated
February 28, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will not share